Epidemiological Evidence for a Low Abuse Potential of Zolpidem

M. Soyka; R. Bottlender; H.-J. Möller

doi:10.1055/s-2000-11224

Pharmacopsychiatry, Inhaltsverzeichnis

Pharmacopsychiatry 2000; 33(4): 138-141
DOI: 10.1055/s-2000-11224

Original Paper

Epidemiological Evidence for a Low Abuse Potential of Zolpidem

M. Soyka, R. Bottlender, H.-J. Möller

Psychiatric Hospital, University of Munich, Munich, Germany

Abstract

The abuse risk of new non-benzodiazepine hypnotics such as zolpidem has been discussed in a number of recent publications. We performed a Medline analysis which showed that, to date, 15 cases of abuse or dependence have been published. In 6 patients, the abuse was secondary to other forms of abuse or dependence. Other data from medical statistics and pharmacoepidemiological studies suggest the abuse potential of zolpidem to be much lower than that of other hypnotics. We conclude that zolpidem is a relatively safe drug compared to conventional hypnotics. Patients with other substance abuse histories may be considered as risk patients for later abuse of zolpidem.

Volltext

Referenzen

References

1 Allain H, Monti J. General safety profile of zolpidem: Safety in elderly, overdose and rebound effects. European Psychiatry. 1997; 12 ((Suppl. 1)) 21-29
2 Annseau M, Pitchot W, Hansenne M. et al . Psychotic reactions to zolpidem. Lancet. 1992; 339 809
3 Arzneimittelkommission der deutschen Ärzteschaft . Keine Verordnung von Zolpidem bei bekannter Benzodiazepinabhängigkeit. Dt Ärzteblatt. 1999; 96 B-500
4 Besset A, Tafti M, Biliard M. Effects of zolpidem on sleep architecture and daytime psychomotor skills in poor sleepers. In: Abstract books, 10th congress of the European Sleep Research Society, Strasbourg, Adis 20 - 25 May 1990: 138
5 Borbe`ly A, Youmbi-Balderer G, Jaggi-Schwarz K. Zolpidem (10 mg and 20 mg): hypnotic action and residual effects after a single bedtime dose. In: Sauvanet JP, Lager SZ, Morselli PL, eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. LERS Monograph series, New York: Raven Press . 1988; 6 205-210
6 Bottlender R, Schütz C, Möller H J, Soyka M. Zolpidem Dependence in a Patient with Former Polysubstance Abuse. Pharmacopsychiat.. 1997; 30 108
7 Bruun T G. Misbrugspotentiale under brug og abstinenspsykose efter behandling med sovemidlet zolpidem (Stilnoct). Ugeskr Laeger. 1993; 155 2711-2712
8 Cavallaro R, Regazetti M G, Smeraldi E. Tolerance and withdrawal with zolpidem. Lancet. 1992; 342 374-375
9 Chamorro-Garcia L, Martin M, De-Dios-Molina J. Zolpidem dependence. Med. Clin.. 1996; 106/12 478-479
10 Clarenbach P. Neue Schlafmittel: Zopiclon und Zolpidem. Arzneimitteltherapie. 1996; 23 82-87
11 Depoortere H, Zivkovic B, Lloyd K. et al . Zolpidem, a novel non-benzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J. Pharmacol. Exp. Ther.. 1986; 237 (2) 649-658
12 Depoortere H, Zivkovic B, Lloyd K G, Sanger J, Perrault G, Langer S Z, Bartholini G. Zolpidem, a novel nonbenzodiazepine hypnotic, I. Neuropharmacological and behavioral effects. J. Pharmacol. Exp. Ther.. 1986; 237 649-658
13 Dujardin K, Guieu J D, Leconte-Lambert C, Leconte P, Borderies P, de La Giclais B. Comparison of the Effects of Zolpidem and Flunitrazepam on Sleep Structure and Daytime Cognitive Functions. Pharmacopsychiat.. 1998; 31 14-18
14 Evans S M, Funderburk F R, Griffiths R R. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J. Pharmacol. Exp. Ther.. 1990; 255 (3) 1246-1255
15 Gericke C A, Ludolph A C. Chronic abuse of zolpidem. JAMA. 1994; 22 272
16 Glaeske G. Psychotrope und andere Arzneimittel mit Mißbrauchs- und Abhängigkeitspotential. In: DHS (ed). Jahrbuch Sucht, Geestacht: Neuland. 1996; 97 32-54
17 Griffiths R R, Sannerud C A, Ator N, Brady J V. Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J. Pharmacol. Exp. Ther.. 1992; 260 1199-1208
18 Guazelli M, Ciapparelli A, Balsamo E L. et al. . Terapia dell'insomnia correlata con i disturbi depressivi. Studio in doppio cieco sugli effetti della somministrazione e della sospensione die zolpidem versus flunitrazepam in pazienti depressi insonni. Minerva Psichiatria. 1993; 34 193-203
19 Hofmann M, Eichhorn M. Ungestilltes Verlangen: Abhangigkeitssyndrom von Zolpidem (Stilnox). Psychiatr-Prax.. 1998 Nov.; 25 (6) 313
20 Iruela L M, Ibanez-Rojo V, Baca E. More on Zolpidem side effects. Lancet 1993a: 1495-1496
21 Iruela L M, Ibanez-Rojo V, Baca E. Zolpidem-induced macropsia in anorexic woman. Lancet 1993b: 443-444
22 Keup W. Zolpidem and Zopiclon. Geringeres Mißbrauchspotential im Vergleich mit Benzodiazepin-Hypnotika. Arzneimitteltherapie. 1999; 16 246-253
23 Keup W. Mißbrauchsmuster bei Abhängigkeit von Alkohol, Medikamenten und Drogen. Frühwarnsystem-Daten für die Bundesrepublik Deutschland 1976 - 1990. Lambertus Verlag, Freiburg 1993
24 Kurtz D, Baas V, Rumbach L. Effects de l'administration répétée de zolpidem 10 mg sur le sommeil et la vigilance diurne chez des mauvais dormeurs. In: Abstract book of the Symposium Stilnox1st Imidazopyridine. 10th Congress of the European Sleep Research Society. Straßbourg. 1990; 20-25 May 1990 143-151
25 Lader M, Russel L. Guidelines for the prevention and treatment of benzodiazepine dependence: summary of a report from the Mental Health Foundation. Addiction. 1993; 88 1707-1708
26 Lader M. Rebound insomnia and newer hypnotics. Psychopharmacology. 1992; 108 248-255
27 Lader M. Zopiclone: Is there any dependence and abuse potential?. J. Neurol.. 1997; 244 (Suppl. 1) 18-22
28 Langer S, Arbilla S. Limitations of the benzodiazepine receptor nomenclature: a proposal for a pharmacological classification as omega receptor subtypes. Fundam. Clin. Pharmacol.. 1988; 2 (3) 159-170
29 Lemoine P, Allain H, Janus C. et al . Gradual withdrawal of zopiclone (7,5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months. Eur. Psychiatry.. 1995; 10 (suppl. 3) 161s-165s
30 Lorizio A, Terzano M, Parrino L. Controlled study of efficacy and safety of two oral doses of zolpidem ( 10 and 20 mg). In: Sauvanet JP, Lager SZ, Morselli PL, eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. LERS Monograph series. New York: Raven Press. 1988; 6 385
31 Maarek L, Cramer P, Attalo P. et al . The safety and efficicacy of zolpidem in insomniac patients: a long-term open study in general practice. J. Int. Med. Res.. 1992; 20 162-170
32 Maggioni M, Frattola L. Double-blind controlled study of the efficacy and safety of zolpidem versus flunitrazepam. In: Sauvanet JP, Lager SZ, Morselli PL, eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. LERS Monograph series. New York: Raven Press . 1988; 6 386-387
33 Merlotti L, Roehrs T, Koshorek G. et al . The dose effects of zolpidem on the sleep of healthy normals. J. Clin. Psychopharmacol.. 1989; 9 9-14
34 Monti J. Effect of zolpidem on sleep in insomniac patients. Eur. J. Clin. Pharmacol.. 1989; 36 461-466
35 Monti J M, Attali P, Monti D, Zipfel A, De la Giclais B, Morselli P L. Zolpidem and rebound insomnia. A double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatria. 1994; 27 166-175
36 Morselli P L. Zolpidem side effects. Lancet 1993: 868-869
37 Müller W E. Wie „neu” sind die Hypnotika Zopiclon und Zolpidem?. Arzneiverordnung in der Praxis. 1994; 2 6-8
38 Pagot R, Cramer P, L'Heritier C. et al . Comparison of the efficacy and tolerability of zolpidem 20 mg and triazolam 0.5 mg in anxious or depressed insomniac patients. Curr. Ther. Res.. 1993; 53 88-97
39 Perrault G, Morel E, Sanger D, Zivokovic B. Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics. Eur. J. Pharmacol.. 1990; 187 (3) 487-494
40 Perrault G, Morel E, Sanger D J, Zivkovic B. Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J. Pharmacol. Exp. Ther. 1992; 263 ((1)) 298-303
41 Ravishankar A, Carnwath T. Zolpidem tolerance and dependence - two case reports. J. Psychopharmacology. 1998; 12 103-104
42 Richens A, Mercer A J, Jones D M, Griffiths A, Marshall R W. Effects of zolpidem on saccadic eye movements and psychomotor performance: a double-blind, placebo cotrolled study in healthy volunteers. Br. J. Clin. Pharmacol. 1993;
43 Roehrs T A, Roth T, Scharf M. et al .Rebound insomnia potential of zolpidem 10 mg as evaluated by three different methods (Abstract). Presented at: Association of Professional Sleep Societies Annual Meeting, Phoenix, Arizona, USA 29 May - 3 June 1992: 134
44 Sakkas P, Psarros C, Masdrakis V, Liappas J, Christodoulou G N. Dependence on zolpidem: a case report. Eur. Psychiatry. 1999; Oct, 14 (6) 358-359
45 Sanchez L G, Sanchez J M, Lopez-Moreno J. Dependence and tolerance with zolpidem (letter). Am. J. Health Syst. Pharm.. 1996; 53 (21) 26-38
46 Sanger D, Zivkovic B. Differential development of tolerance to the depressant effects of benzodiazepine and non-benzodiazepine agonists at the omega modulatory sites of GABA A receptors. Neuropharmacology. 1992; 31 (7) 693-700
47 Sanger D J, Zivkovic B. Discriminative stimulus properties of chlordiazepoxide and zolpidem. Agonist and antagonist effects of CGS 9896 and ZK 91296. Neuropharmacol.. 1987; 26 499-595
48 Sanger D J, Zivkovic B. The discriminative stimulus properties of zolpidem, a novel imidazopyridine hypnotic. Psychopharmacol.. 1986; 89 317-322
49 Sakkas P, Psarros C, Masdrakis V, Liappas J, Christodoulou G N. Dependence on zolpidem: case report. Eur. Psychiatry. 1999; 14 358-359
50 Sauvanet J P, Maarek L, Roger M, Renaudin J, Luovel E, Orafiamma B. Open long-term trials with zolpidem in insomnia. In: Sauvanet JP, Lager SZ, Morselli PL, eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. (LERS Monograph series; vol. 6). New York: Raven Press. 1988; 6 339-349
51 Sauvanet J P, Maarek L, Roger M. Open long-term trials with zolpidem in insomnia. In: Sauvanet JP, Langer SZ, Morselli PL (ed.): Imidazopyridines in Sleep Disorders. New York: Raven Press. 1988: 339-349
52 Schadeck B, Chelly M, Amsellem D. et al. . Efficacité comparative de la doxylamine (15 mg) et du zolpidem (10 mg) dans le traitement de l'insomnie commune. Sem. Hop.. 1996; 72 428-439
53 Scharf M B, Vogel G, Kaffeman M, Ochs R F. Dose-response of zolpidem in elderly patients with chronic insomnia. Sleep Res.. 1991b; 20 84
54 Schlich D, L'Heritier C, Coquelin J, Attali P. Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J. Int. Med. Res.. 1991; 19 271-279
55 Ströhle A, Antonijevic I A, Steiger A, Sonntag A. Dependency of non-benzodiazepine hypnotics. Two case reports. Nervenarzt. 1999; 70, 1 72-75
56 Thome J, Ruchsow M, Rössler M. et al . Zolpidem-Abhängigkeit und Depression im Senium. Psychiatr. Prax.. 1995; 22 165-166
57 Vogel G, Poirrier R. Studies of effects following discontinuation of zolpidem treatment. In: Freeman H, Puech AJ, Roth T (eds) Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Amsterdam Oxford: Elsevier 1996: 149-160
58 Weerts E M, Griffiths R R. Zolpidem self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. Behav-pharmacol.. 1998; 9 (3) 285-297
59 Wheatley D. Prescribing short-acting hypnosedatives. Current recommendations from a safety perspective. Drug Safety. 1992; 7 (2) 106-115

1 Glaeske model, definition of long-term users; patients who continue to use a drug for more than 90 days following the first prescription.

2 AOK model (AOK refers to the „Allgemeine Ortskrankenkassen”, a major public health insurance in Germany), definition of long-term users: patients who in each of the 4 quarters following the first prescription still take at least half of a DDD.

Dr. med. M. Soyka

Psychiatrisches Krankenhaus, Universität München

Nussbaumstraße 7

80336 Munich

Germany